Laser Treatment of Hair Loss: An Update and Literature Review

Background: Hair loss, particularly androgenetic alopecia and alopecia areata, represents a prevalent dermatological condition with significant psychosocial impact. Laser-based therapies have emerged as promising non-invasive treatment modalities, encompassing low-level laser therapy (LLLT), fractional ablative lasers, and photobiomodulation techniques. Recent technological advances have introduced novel wavelengths, treatment parameters, and combination approaches that demonstrate enhanced efficacy profiles. This comprehensive review examines the current state of laser therapy for hair loss, analyzing clinical outcomes, mechanisms of action, and safety considerations reported between 2023 and 2025. Methods: A systematic literature search was conducted using MEDLINE, PubMed, and Ovid databases for studies published between January 2023 and December 2025. Keywords included “laser hair loss,” “low-level laser therapy,” “LLLT,” “photobiomodulation,” “fractional laser,” “androgenetic alopecia,” “alopecia areata,” “erbium YAG laser,” and “CO2 laser.” Studies were classified according to the Oxford Centre for Evidence-Based Medicine levels of evidence hierarchy. Forty-three studies were analyzed, including randomized controlled trials, cohort studies, case series, systematic reviews, and meta-analyses. Results: Low-level laser therapy demonstrated hair density increases of 15–40% across multiple studies, with wavelengths between 630–680 nm showing optimal efficacy. Fractional CO2 lasers achieved 30–75% improvement in hair regrowth when combined with topical therapies, with mechanisms involving stem cell activation and enhanced drug delivery. Erbium:YAG lasers showed promising results with 40–65% response rates and favorable safety profiles. Combination approaches with minoxidil, platelet-rich plasma, or bimatoprost demonstrated superior outcomes compared to monotherapy. Common complications included transient erythema (60–90%), mild pain during treatment (40–70%), temporary shedding (15–30%), and rare cases of hyperpigmentation (2–8%). Meta-analyses confirmed significant efficacy advantages for combination therapies over single-modality treatments. Conclusion: Laser-based therapies represent effective treatment options for various hair loss conditions, with evidence supporting both low-level laser therapy and fractional ablative approaches. Combination strategies demonstrate superior efficacy compared to monotherapy. Patient selection, appropriate laser parameter selection, and realistic expectation management remain essential for optimizing outcomes. Future research should focus on standardized treatment protocols, long-term efficacy data, and identification of predictive biomarkers for treatment response.